Omnicell, Inc. (NASDAQ:OMCL) fell 5.5% during mid-day trading on Thursday . The company traded as low as $69.30 and last traded at $70.59. 977,205 shares traded hands during trading, an increase of 194% from the average session volume of 332,596 shares. The stock had previously closed at $74.72.
A number of brokerages have issued reports on OMCL. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Cantor Fitzgerald reiterated a “buy” rating and set a $80.00 price objective (up from $70.00) on shares of Omnicell in a research note on Thursday. Craig Hallum increased their price objective on shares of Omnicell from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, September 17th. Zacks Investment Research reiterated a “strong-buy” rating and set a $78.00 price objective on shares of Omnicell in a research note on Wednesday, November 14th. Finally, Benchmark increased their price objective on shares of Omnicell from $66.00 to $79.00 and gave the stock a “buy” rating in a research note on Friday, October 5th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $72.13.
The company has a current ratio of 1.78, a quick ratio of 1.32 and a debt-to-equity ratio of 0.27. The company has a market cap of $2.96 billion, a price-to-earnings ratio of 392.17, a P/E/G ratio of 4.46 and a beta of 0.99.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 25th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The company had revenue of $204.27 million for the quarter, compared to the consensus estimate of $203.48 million. On average, equities research analysts forecast that Omnicell, Inc. will post 1.42 EPS for the current year.
In related news, Director James T. Judson sold 2,443 shares of Omnicell stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $70.67, for a total transaction of $172,646.81. Following the sale, the director now directly owns 24,952 shares in the company, valued at approximately $1,763,357.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Dan S. Johnston sold 6,250 shares of Omnicell stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $63.47, for a total transaction of $396,687.50. Following the sale, the executive vice president now owns 35,996 shares in the company, valued at $2,284,666.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,267 shares of company stock worth $1,309,116. 3.71% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. West Coast Financial LLC raised its holdings in Omnicell by 3.7% during the 3rd quarter. West Coast Financial LLC now owns 115,580 shares of the company’s stock worth $8,310,000 after purchasing an additional 4,126 shares during the last quarter. Kopp Investment Advisors LLC raised its holdings in Omnicell by 2.6% during the 2nd quarter. Kopp Investment Advisors LLC now owns 69,077 shares of the company’s stock worth $3,623,000 after purchasing an additional 1,757 shares during the last quarter. Everence Capital Management Inc. bought a new position in Omnicell during the 3rd quarter worth approximately $204,000. Janus Henderson Group PLC raised its holdings in Omnicell by 52.1% during the 2nd quarter. Janus Henderson Group PLC now owns 1,513,979 shares of the company’s stock worth $79,408,000 after purchasing an additional 518,824 shares during the last quarter. Finally, Zebra Capital Management LLC bought a new position in Omnicell during the 2nd quarter worth approximately $802,000.
ILLEGAL ACTIVITY WARNING: “Omnicell (OMCL) Shares Down 5.5%” was posted by Zolmax and is the property of of Zolmax. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://zolmax.com/investing/omnicell-omcl-shares-down-5-5/2747335.html.
About Omnicell (NASDAQ:OMCL)
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Read More: How can investors find ex-dividend dates?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.